Purespring Therapeutics names new CEO

UK-based Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its chief executive (CEO) and member of the board of directors effective immediately.

Mr Ahmad has been appointed to steer Purespring through a critical phase of development and growth. He brings significant senior industry leadership, joining Purespring with over 25 years in the life science industry and an impressive track record of leading organisations to create blockbuster brands from primary care to rare diseases, across both mature and growth markets.

Mr Ahmad most recently served as president of Novartis Europe where he oversaw $15 billion in revenue across 53 markets. Prior to this, he led Novartis Gene Therapies to bring first-class, potentially curative gene therapies to patients, including Zolgensma, the first blockbuster gene therapy worldwide. Previously Mr Ahmad held numerous global and in country leadership roles at Novartis (NOVN: VX) and Merck & Co (NYSE: MRK). He succeeds Julian Hanak, who has served as CEO since December 2022 and previous to that CDO since June 2021.